CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
Investing.com - Harvard Bioscience (NASDAQ: HBIO) reported first quarter EPS of $0.060, better than the analyst estimate of $0.050. Revenue for the quarter came in at $24.6M versus the consensus estimate of $24.15M.
Guidance
Harvard Bioscience sees Q1 2025 revenue of $19.000M-$21.000M
Harvard Bioscience’s stock price closed at $0.76. It is down -64.720% in the last 3 months and down -82.640% in the last 12 months.
Harvard Bioscience saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Harvard Bioscience’s stock price’s past reactions to earnings here.
According to InvestingPro, Harvard Bioscience’s Financial Health score is "fair performance".
Check out Harvard Bioscience’s recent earnings performance, and Harvard Bioscience’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar